|
 Samaritan
Pharmaceuticals Inc. is pleased to announced today that the
company has closed its acquisition of Metastatin Pharmaceuticals,
Inc., a biopharmaceutical company focused on molecularly targeted
Cancer drugs to control tumor progression and metastasis.
Lane Capital Markets
served as an advisor in connection with this transaction.
About Samaritan
Pharmaceuticals: ``We LIV....to Save Lives.''
Samaritan is a
small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics' for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
Samaritan Pharmaceuticals
-- Samaritan Technology Videos: http://www.samaritanpharma.com/samaritan_mechanism_of_action_videos.asp
The company disclaims
any information that is created by an outside party and endorses
only information that is communicated by its press releases,
filings and Website. This news release contains forward-looking
statements that reflect management's current beliefs about
the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development,
there are significant risks and uncertainties in the process
of development and regulatory review. There are no guarantees
that products will prove to be commercially successful. For
additional information about the factors that affect the company's
business, please read the company's latest Form 10-K/A filed
November 2, 2006. The company undertakes no duty to update
forward-looking statements.
Contact:
Samaritan Pharmaceuticals, Inc.
Richard Brown
(702) 735-7001
richardbrown@SamaritanPharma.com
|
